Live Breaking News & Updates on Enzyme Activity Component|Page 1
Stay updated with breaking news from Enzyme activity component. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- New clinical biomarker data from Phase 1 monotherapy trial of RBN-2397 provide evidence for immune cell infiltration in patient tumors upon treatment, providing strong rationale for combining with immune checkpoint inhibitors- Preclinical studies provide further insight into the cancer cell-intrinsic mechanism of. ....
Ribon Therapeutics, a Cambridge, Mass.-based clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, closed a $65m financing. The round was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation – JJDC, Inc., Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group. The company will use the proceeds to support the clinical development of its novel precision medicine candidates. Led by Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that cont ....